Company Encyclopedia
View More
name
Sonoma Pharma
SNOA.US
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
4.514 T
SNOA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking103/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-76.14%E
    • Profit Margin-20.54%D
    • Gross Margin37.83%B
  • Growth ScoreB
    • Revenue YoY25.02%A
    • Net Profit YoY5.62%C
    • Total Assets YoY1.25%C
    • Net Assets YoY-29.24%E
  • Cash ScoreC
    • Cash Flow Margin-486.84%E
    • OCF YoY25.02%A
  • Operating ScoreA
    • Turnover1.23A
  • Debt ScoreD
    • Gearing Ratio72.67%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results | SNOA Stock News

    Sonoma Pharmaceuticals reported a 57% increase in revenues for Q2 2026, totaling $5.6 million, marking the highest quarterly revenue in the company's history. U.S. revenues surged by 115%, driven by strong sales of over-the-counter products. The net loss per share decreased by 46% compared to the previous year. The company continues to expand its product offerings and distribution network, including new partnerships and product launches. Overall, Sonoma anticipates a positive growth trajectory in the HOCl industry, with increasing adoption of its products.

    StockTitan·
    US
    SNOA
    +12.97%
    StockTitan·
    US
    SNOA
    +12.97%

    Sonoma Pharma | 10-Q: FY2026 Q2 Revenue: USD 5.604 M

    LB filings·
    US
    SNOA
    +12.97%
    LB filings·
    US
    SNOA
    +12.97%

    Sonoma Pharmaceuticals Announces Termination of Executive Vice President

    On October 18, 2025, Sonoma Pharmaceuticals, Inc. announced the immediate termination of Bruce Thornton as Executive Vice President and Chief Operating Officer for cause, as per his employment agreement. Replacement information has not been disclosed. This announcement was filed with the SEC under the original filing number SNOA - 8-K on October 23, 2025.

    TradingView·
    US
    SNOA
    +12.97%
    TradingView·
    US
    SNOA
    +12.97%

    Sonoma Pharmaceuticals Highlights Growth in Healthcare Sector

    Sonoma Pharmaceuticals (SNOA) has announced its growth in the healthcare sector, highlighting its expanded wound care business through partnerships with major distributors like Medline Industries. The company has introduced new applications for its Microcyn technology and maintains a strong regulatory portfolio. Analysts rate SNOA stock as a Hold with a $4.00 price target, while Spark's AI Analyst gives it a Neutral rating. Despite strong revenue growth, challenges in profitability and cash flow management suggest caution for potential investors. Sonoma specializes in stabilized hypochlorous acid products used in various healthcare applications.

    Tip Ranks·
    US
    SNOA
    +12.97%
    Tip Ranks·
    US
    SNOA
    +12.97%

    Sonoma Pharmaceuticals Enters Sales Agreement with Ladenburg

    Sonoma Pharmaceuticals (SNOA) has entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. to sell shares of its common stock, allowing for various sale methods. The agreement, effective September 26, 2025, is for an aggregate offering price of up to $2,070,463 under a SEC registration statement. Analysts rate SNOA stock as Hold with a $4.00 price target, citing strong revenue growth but challenges in profitability and cash flow. Technical analysis shows weak momentum, suggesting caution for investors.

    Tip Ranks·
    US
    SNOA
    +12.97%
    Tip Ranks·
    US
    SNOA
    +12.97%
    © 2025 Longbridge｜Disclaimer